Apellis Pharmaceuticals Inc (APLS): Next-Year EPS Estimate 74.86%
As of 2026-05-28, Apellis Pharmaceuticals Inc (APLS) has a next-year EPS growth estimate of 74.86%.
On 2026-05-24, analyst consensus for APLS's next-year EPS growth shifted from 77.74% to 74.86% — a negative change of 2.88 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at -665.00%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 74.86%
- EPS growth this year
- -665.00%
- EPS next quarter (est)
- -$0.24
- Last price
- $41.03
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-28 | 74.86% | -665.00% | -$0.24 | $41.03 |
| 2026-05-27 | 74.86% | -665.00% | -$0.24 | $41.03 |
| 2026-05-26 | 74.86% | -665.00% | -$0.24 | $41.03 |
| 2026-05-25 | 74.86% | -665.00% | -$0.24 | $41.03 |
| 2026-05-24 | 74.86% | -665.00% | -$0.24 | $41.03 |
| 2026-05-21 | 77.74% | -662.22% | -$0.26 | $41.03 |
| 2026-05-20 | 81.27% | -666.50% | -$0.27 | $41.03 |
| 2026-05-19 | 88.26% | -667.30% | -$0.27 | $41.03 |
| 2026-05-18 | 88.26% | -667.30% | -$0.27 | $41.03 |
| 2026-05-17 | 91.95% | -632.72% | -$0.27 | $41.03 |
| 2026-05-14 | 93.06% | -613.79% | -$0.28 | $41.03 |
| 2026-05-13 | 92.62% | -617.87% | -$0.27 | $41.06 |
| 2026-05-12 | 92.62% | -617.87% | -$0.27 | $41.06 |
| 2026-05-11 | 92.62% | -617.87% | -$0.27 | $41.02 |
| 2026-05-10 | 92.20% | -629.46% | -$0.29 | $41.03 |
| 2026-05-07 | 89.92% | -639.94% | -$0.31 | $41.01 |
| 2026-05-06 | 88.67% | -657.91% | -$0.34 | $41.12 |
| 2026-05-05 | 88.67% | -657.91% | -$0.34 | $40.97 |
| 2026-05-04 | 88.67% | -657.91% | -$0.34 | $40.97 |
| 2026-05-03 | 88.67% | -657.91% | -$0.34 | $40.96 |
| 2026-04-30 | 88.67% | -657.91% | -$0.34 | $40.95 |
| 2026-04-29 | 88.67% | -657.91% | -$0.34 | $40.95 |
| 2026-04-28 | 88.67% | -657.91% | -$0.34 | $40.99 |
| 2026-04-27 | 88.67% | -657.91% | -$0.34 | $40.95 |
| 2026-04-26 | 88.67% | -657.91% | -$0.34 | $40.94 |
| 2026-04-24 | 88.67% | -657.91% | -$0.34 | $40.94 |
| 2026-04-23 | 88.67% | -657.91% | -$0.34 | $40.94 |
| 2026-04-22 | 88.67% | -657.91% | -$0.34 | $40.89 |
| 2026-04-21 | 88.67% | -657.91% | -$0.34 | $40.94 |
| 2026-04-20 | 88.67% | -657.79% | -$0.34 | $40.94 |
Recent News
- Disney upgraded, Nike downgraded: Wall Street's top analyst callsThe Fly
- Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutPharmaceutical Technology
- The Year Is Off to the Strongest Start for Big Deals EverThe Wall Street Journal
- Big Drug Companies Hunting for Deals Are Lowering Their SightsThe Wall Street Journal
- Big Drug Companies Hunting for Deals Are Lowering Their SightsThe Wall Street Journal
- Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs.Barrons.com
- Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on AnnouncementGuruFocus.com
- Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on AnnouncementGuruFocus.com
- Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolioProactive
- Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolioProactive
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Apellis Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-05-28, Apellis Pharmaceuticals Inc (APLS) has a next-year EPS growth estimate of 74.86%, based on analyst consensus.
When was the latest EPS estimate revision for APLS?▾
The most recent revision occurred on 2026-05-24, when analysts adjusted the next-year EPS growth estimate from 77.74% to 74.86%.
What sector and industry does Apellis Pharmaceuticals Inc belong to?▾
Apellis Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. APLS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Apellis Pharmaceuticals Inc (APLS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports